Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Novartis Pharmaceuticals
The Children's Tumor Foundation
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT01419639
First received: August 17, 2011
Last updated: November 9, 2012
Last verified: August 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: October 2013
  Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)